Table 1 Comparison of clinical characteristics between the two groups of PSS patients
With PN (N = 15) | Without PN (N = 45) | t/Z/x2 | P | |
|---|---|---|---|---|
Age (years) | 55.47 ± 15.51 | 56.18 ± 13.81 | 0.168 | 0.868 |
Disease duration (years)a | 7 (6, 10) | 4 (3,5) | − 3.225 | 0.001 |
Female [n (%)] | 12 (80.0) | 38 (84.4) | 0.000 | 1.000 |
Dry mouth [n (%)] | 10 (66.7) | 40 (88.9) | 2.560 | 0.110 |
Dry eyes [n (%)] | 9 (60.0) | 37 (82.2) | 1.988 | 0.159 |
Swollen parotid gland [n (%)] | 8 (53.3) | 16 (35.6) | 0.244 | 0.621 |
Raynaud phenomenon [n (%)] | 9 (60.0) | 13 (28.9) | 5.770 | 0.016 |
Arthralgia [n (%)] | 6 (40.0) | 18 (40.0) | 0.000 | 1.000 |
Skin rash [n (%)] | 7 (46.7) | 13 (28.9) | 1.600 | 0.206 |
Renal damage [n (%)] | 5 (33.3) | 10 (22.2) | 0.267 | 0.606 |
Positive anti-SSA antibody [n (%)] | 13 (86.7) | 40 (88.9) | 0.00 | 1.000 |
Positive anti-SSB antibody [n (%)] | 12 (80.0) | 20 (44.4) | 5.714 | 0.017 |
Positive RF [n (%)] | 10 (66.7) | 18 (40.0) | 4.434 | 0.035 |
Cryoglobulinaemia [n (%)] | 6 (40.0) | 14 (31.1) | 0.400 | 0.527 |
Hyperglobulinaemia [n (%)] | 11 (73.3) | 15 (33.3) | 10.71 | 0.001 |
Decreased complement C4 [n (%)] | 7 (46.7) | 12 (26.7) | 1.258 | 0.262 |
Elevated ESR [n (%)] | 8 (53.3) | 17 (37.8) | 1.120 | 0.290 |
Elevated CRP [n (%)] | 9 (60.0) | 15 (33.3) | 3.333 | 0.068 |
ESSDAIa | 9 (17,2) | 5 (14, 2) | 0.189 | 0.850 |
ESSPRIa | 5 (4,5) | 4 (3, 5) | 0.304 | 0.761 |